Business Wire

BENTLEY-SYSTEMS

7.4.2022 22:03:11 CEST | Business Wire | Press release

Share
Bentley Systems Announces Acquisition of ADINA to Extend Nonlinear Simulation throughout Infrastructure Engineering

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced it has acquired Watertown, Massachusetts-based ADINA R & D Inc., a leading developer of finite element analysis software applications used in a comprehensively diverse range of engineering fields (adina.com ). ADINA was founded in 1986 by Dr. Klaus-Jürgen Bathe, professor of mechanical engineering at the Massachusetts Institute of Technology and a world-renowned leader in the field of finite element analysis and its applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406006024/en/

Civil, structural, and mechanical engineers choose ADINA software for its authoritative veracity, including in analysis of buildings, bridges, stadiums, pressure vessels, dams, and tunnels. By virtue of the ADINA System’s integral robustness across disciplines, materials, and simulation domains (structures, mechanical, fluids, thermal, electromagnetic, and multi-physics), engineers use it to perform comprehensive safety and performance studies where reliability and resilience are of critical importance.

With infrastructure digital twins, users can simulate the complete behavior of structures to create confidence in designs that are much safer and more cost-effective than those merely analyzed to meet prescribed code standards. Of particular importance for infrastructure resilience, ADINA will also be applied within digital twins of existing infrastructure assets, now made practical by the Bentley iTwin platform, to simulate their responses and vulnerabilities to stresses so extreme that nonlinear effects must be considered—caused (for instance) by seismic, wind, flood, pressure, thermal, collision, or blast forces.

The ADINA System’s nonlinear simulation capabilities will in turn become directly accessible, through convenient technical and commercial integration, to users of Bentley Systems’ uniquely comprehensive modeling and simulation software portfolio for infrastructure engineering. As the ADINA System’s nonlinear extensions are introduced to complement these existing physical simulation applications—currently spanning STAAD, RAM, SACS, MOSES, AutoPIPE, PLAXIS, LEAP, RM, LARS, SPIDA, and PLS—the scope of mainstream simulation underlying the engineering of infrastructure resilience will be valuably enhanced. ADINA’s advantages also include advanced dynamics, 3D solid FEM, buckling, substructuring, and advanced meshing for critical joints and sections.

“Incorporating ADINA and its creators is very exciting for all of our engineering simulation teams, as it will also be for existing and new users,” said Raoul Karp, vice president, engineering simulation at Bentley Systems. “Dr. Bathe literally wrote the book on advancing finite element simulations, and the ADINA System provides the reference for benchmarking all other disparate analysis approaches. We will now be able to extend nonlinear realism across all of our infrastructure digital twin simulation offerings.”

Founder of ADINA Dr. K.J. Bathe, who will remain as a technical advisor, said, “My colleagues and I are proud to be joining Bentley Systems’ broad and deep simulation team. Our aim in the development of ADINA has always been to provide a most reliable and efficient analysis tool to scientists and engineers, and it is wonderful that with Bentley, ADINA will now be used and further developed with great potential for solving the varied and interrelated challenges of infrastructure resilience.”

Image 1 :
Caption: The frictional sliding of a prestressed concrete bridge girder can be studied with ADINA technology.

Image 2 :
Caption: Collapse analysis of pressurized pipe can be performed with ADINA software.

Image 3 :
Caption: Simulation of a pipe break in a nuclear reactor using ADINA technology.

Image 4 :
Caption: Sloshing of an oil tank with the base subjected to horizontal ground motion with ADINA software.

##

About Bentley Systems

Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation -based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geoprofessional software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,500 colleagues and generates annual revenues of approximately $1 billion in 186 countries.
www.bentley.com

© 2022 Bentley Systems, Incorporated. Bentley, the Bentley logo, ADINA, AssetWise, AutoPIPE, iTwin, LARS, LEAP, SPIDA, MicroStation, MOSES, PLAXIS, PLS, ProjectWise, RAM, RM, SACS, Seequent, and STAAD are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye